• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

法昔洛韦及其主要代谢物 OP-1118 对艰难梭菌的杀菌动力学。

Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

机构信息

Optimer Pharmaceuticals, San Diego, CA, USA.

出版信息

J Med Microbiol. 2011 Aug;60(Pt 8):1213-1217. doi: 10.1099/jmm.0.029470-0. Epub 2011 Feb 24.

DOI:10.1099/jmm.0.029470-0
PMID:21349983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3167880/
Abstract

The kinetics of bacterial killing for fidaxomicin and its major metabolite, OP-1118, were investigated against Clostridium difficile strains, including two clinical strains belonging to the restriction endonuclease analysis group BI (ORG 1687 and 1698), the ATCC 43255 strain and two laboratory-derived mutant strains with decreased susceptibility to fidaxomicin (ORG 919 and 1620). Both fidaxomicin and OP-1118 demonstrated time-dependent killing of C. difficile strains. Fidaxomicin (at 4× MIC) reduced bacterial counts of the ATCC 43255 strain, clinical strain ORG 1687 and the two laboratory-generated mutant strains by ≥3 logs within 48 h of exposure. The other BI strain, ORG 1698, was tested at 2× MIC fidaxomicin with bacterial counts decreasing 1 log in 48 h. Exposure to OP-1118 (at 4× MIC) also resulted in a ≥3 log drop in c.f.u. counts for the ATCC 43255 strain, the clinical BI strain ORG 1687 and the mutant strain ORG 919. Higher concentrations of OP-1118 (32× MIC) were required for a 3 log reduction in c.f.u. counts for the other BI strain, ORG 1698. In summary, the results indicate that both fidaxomicin and its major metabolite, OP-1118, are bactericidal against C. difficile strains, including the hypervirulent restriction endonuclease analysis group BI strains, at concentrations that are many fold below the detected faecal concentrations of these compounds after oral administration of fidaxomicin.

摘要

研究了非达霉素及其主要代谢物 OP-1118 对艰难梭菌菌株的杀菌动力学,包括属于内切酶分析组 BI 的两个临床菌株(ORG 1687 和 1698)、ATCC 43255 菌株和两个对非达霉素敏感性降低的实验室衍生突变株(ORG 919 和 1620)。非达霉素和 OP-1118 均表现出对艰难梭菌菌株的时间依赖性杀菌作用。非达霉素(4×MIC)在暴露 48 小时内可使 ATCC 43255 菌株、临床菌株 ORG 1687 和两个实验室产生的突变株的细菌计数减少≥3 对数级。另一个 BI 菌株 ORG 1698 在 2×MIC 非达霉素的测试中,48 小时内细菌计数减少 1 对数级。暴露于 OP-1118(4×MIC)也导致 ATCC 43255 菌株、临床 BI 菌株 ORG 1687 和突变株 ORG 919 的 c.f.u.计数减少≥3 对数级。需要更高浓度的 OP-1118(32×MIC)才能使另一个 BI 菌株 ORG 1698 的 c.f.u.计数减少 3 对数级。总之,结果表明,非达霉素及其主要代谢物 OP-1118 对艰难梭菌菌株均具有杀菌作用,包括高毒力的内切酶分析组 BI 菌株,其浓度是口服非达霉素后粪便中这些化合物检测浓度的许多倍。

相似文献

1
Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.法昔洛韦及其主要代谢物 OP-1118 对艰难梭菌的杀菌动力学。
J Med Microbiol. 2011 Aug;60(Pt 8):1213-1217. doi: 10.1099/jmm.0.029470-0. Epub 2011 Feb 24.
2
Fidaxomicin inhibits spore production in Clostridium difficile.非达霉素抑制艰难梭菌的孢子生成。
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S162-9. doi: 10.1093/cid/cis453.
3
Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. fidaxomicin 和其主要代谢产物 OP-1118 对艰难梭菌的抗生素后效应。
Antimicrob Agents Chemother. 2011 Sep;55(9):4427-9. doi: 10.1128/AAC.00104-11. Epub 2011 Jun 27.
4
Antimicrobial activities of fidaxomicin. fidaxomicin 的抗菌活性。
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S143-8. doi: 10.1093/cid/cis339.
5
Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.两项关于 fidaxomicin 治疗艰难梭菌感染的 III 期临床试验中,收集的基线、复发和失败时患者分离株对 fidaxomicin(OPT-80)的比较药敏性。
Antimicrob Agents Chemother. 2011 Nov;55(11):5194-9. doi: 10.1128/AAC.00625-11. Epub 2011 Aug 15.
6
Fidaxomicin inhibits toxin production in Clostridium difficile. fidaxomicin 抑制艰难梭菌毒素的产生。
J Antimicrob Chemother. 2013 Mar;68(3):515-22. doi: 10.1093/jac/dks450. Epub 2012 Dec 2.
7
Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.非达霉素和万古霉素均可抑制艰难梭菌孢子的生长。
Antimicrob Agents Chemother. 2013 Jan;57(1):664-7. doi: 10.1128/AAC.01611-12. Epub 2012 Nov 12.
8
Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.艰难梭菌生物膜分析:成像与抗菌治疗。
J Antimicrob Chemother. 2018 Jan 1;73(1):102-108. doi: 10.1093/jac/dkx353.
9
Susceptibility of Clostridium species isolated in Japan to fidaxomicin and its major metabolite OP-1118.日本分离出的梭菌属对非达霉素及其主要代谢物OP-1118的敏感性。
J Infect Chemother. 2018 Jun;24(6):492-495. doi: 10.1016/j.jiac.2017.12.006. Epub 2018 Jan 17.
10
and Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile.新型喹诺酮化合物OPS-2071对艰难梭菌的抗菌活性
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.01170-20.

引用本文的文献

1
Fidaxomicin resistance in : a systematic review and predictive modeling with RNA polymerase binding sites.非达霉素耐药性:基于RNA聚合酶结合位点的系统评价与预测建模
Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0120624. doi: 10.1128/aac.01206-24. Epub 2024 Nov 6.
2
Genetic determinants of resistance to antimicrobial therapeutics are rare in publicly available Clostridioides difficile genome sequences.在公开的艰难梭菌基因组序列中,对抗菌治疗有抗性的遗传决定因素很少。
J Antimicrob Chemother. 2024 Jun 3;79(6):1320-1328. doi: 10.1093/jac/dkae101.
3
Novel fidaxomicin antibiotics through site-selective catalysis.通过位点选择性催化的新型非达霉素抗生素。
Commun Chem. 2021 May 10;4(1):59. doi: 10.1038/s42004-021-00501-6.
4
Make It Less : Understanding Genetic Evolution and Global Spread of .使它变少:理解遗传进化和 的全球传播。
Genes (Basel). 2022 Nov 24;13(12):2200. doi: 10.3390/genes13122200.
5
Fidaxomicin for the Treatment of Infection in Adult Patients: An Update on Results from Randomized Controlled Trials.非达霉素用于治疗成年患者感染:随机对照试验结果的最新进展
Antibiotics (Basel). 2022 Oct 6;11(10):1365. doi: 10.3390/antibiotics11101365.
6
Genetic Mechanisms of Vancomycin Resistance in : A Systematic Review.万古霉素耐药性的遗传机制:一项系统综述
Antibiotics (Basel). 2022 Feb 16;11(2):258. doi: 10.3390/antibiotics11020258.
7
Mechanisms and impact of antimicrobial resistance in Clostridioides difficile.艰难梭菌中抗菌药物耐药性的机制及影响
Curr Opin Microbiol. 2022 Apr;66:63-72. doi: 10.1016/j.mib.2022.01.004. Epub 2022 Jan 22.
8
Semisynthetic Analogs of the Antibiotic Fidaxomicin-Design, Synthesis, and Biological Evaluation.抗生素非达霉素的半合成类似物——设计、合成及生物学评价
ACS Med Chem Lett. 2020 Oct 14;11(12):2414-2420. doi: 10.1021/acsmedchemlett.0c00381. eCollection 2020 Dec 10.
9
Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.非达霉素与万古霉素治疗艰难梭菌感染初发 episode:一项荟萃分析与系统评价
Cureus. 2018 Jun 11;10(6):e2778. doi: 10.7759/cureus.2778.
10
Detection and Investigation of Eagle Effect Resistance to Vancomycin in With an ATP-Bioluminescence Assay.采用ATP生物发光法检测和研究万古霉素的鹰效应耐药性
Front Microbiol. 2018 Jul 2;9:1420. doi: 10.3389/fmicb.2018.01420. eCollection 2018.

本文引用的文献

1
A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.一种新型大环抗生素,非达霉素(OPT-80),相较于万古霉素,引起艰难梭菌感染患者肠道微生物群改变更小。
Microbiology (Reading). 2010 Nov;156(Pt 11):3354-3359. doi: 10.1099/mic.0.042010-0. Epub 2010 Aug 19.
2
Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. fidaxomicin (OPT-80) 治疗艰难梭菌感染。
Expert Opin Pharmacother. 2010 Jun;11(9):1569-78. doi: 10.1517/14656566.2010.485614.
3
Clostridium difficile infection: new developments in epidemiology and pathogenesis.艰难梭菌感染:流行病学与发病机制的新进展
Nat Rev Microbiol. 2009 Jul;7(7):526-36. doi: 10.1038/nrmicro2164.
4
Review of current literature on the economic burden of Clostridium difficile infection.艰难梭菌感染经济负担的当前文献综述。
Infect Control Hosp Epidemiol. 2009 Jan;30(1):57-66. doi: 10.1086/592981.
5
OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.OPT-80可清除艰难梭菌,且在治疗艰难梭菌感染期间对拟杆菌属菌种无损害。
Antimicrob Agents Chemother. 2009 Jan;53(1):261-3. doi: 10.1128/AAC.01443-07. Epub 2008 Oct 27.
6
Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.脂臂霉素作用于RNA聚合酶,对耐多药结核分枝杆菌菌株具有良好活性。
J Antimicrob Chemother. 2008 Oct;62(4):713-9. doi: 10.1093/jac/dkn269. Epub 2008 Jun 27.
7
Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.单次和多次口服给药后OPT-80在健康志愿者中的安全性、耐受性和药代动力学研究。
Antimicrob Agents Chemother. 2008 Apr;52(4):1391-5. doi: 10.1128/AAC.01045-07. Epub 2008 Feb 11.
8
Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile.万古霉素、甲硝唑和夫西地酸对艰难梭菌的药效学研究。
Chemotherapy. 2007;53(4):267-74. doi: 10.1159/000104471. Epub 2007 Jun 25.
9
In vitro activities of OPT-80 and comparator drugs against intestinal bacteria.OPT-80及对照药物对肠道细菌的体外活性。
Antimicrob Agents Chemother. 2004 Dec;48(12):4898-902. doi: 10.1128/AAC.48.12.4898-4902.2004.
10
Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.新型大环化合物OPT-80与其他八种药物针对特定厌氧菌种的活性比较。
Antimicrob Agents Chemother. 2004 Nov;48(11):4430-4. doi: 10.1128/AAC.48.11.4430-4434.2004.